|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CD37 |
Gene summary for CD37 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CD37 | Gene ID | 951 |
| Gene name | CD37 molecule | |
| Gene Alias | GP52-40 | |
| Cytomap | 19q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0001772 | UniProtAcc | P11049 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 951 | CD37 | CA_HPV_1 | Human | Cervix | CC | 1.97e-02 | 1.12e-01 | 0.0264 |
| 951 | CD37 | CCI_1 | Human | Cervix | CC | 3.25e-07 | -6.55e-01 | 0.528 |
| 951 | CD37 | CCI_2 | Human | Cervix | CC | 1.54e-06 | -6.55e-01 | 0.5249 |
| 951 | CD37 | CCI_3 | Human | Cervix | CC | 7.02e-07 | -6.24e-01 | 0.516 |
| 951 | CD37 | CCII_1 | Human | Cervix | CC | 4.27e-14 | -6.55e-01 | 0.3249 |
| 951 | CD37 | Tumor | Human | Cervix | CC | 1.20e-34 | -6.55e-01 | 0.1241 |
| 951 | CD37 | sample1 | Human | Cervix | CC | 7.17e-08 | -5.97e-01 | 0.0959 |
| 951 | CD37 | sample3 | Human | Cervix | CC | 1.03e-36 | -6.53e-01 | 0.1387 |
| 951 | CD37 | H2 | Human | Cervix | HSIL_HPV | 8.65e-24 | -6.12e-01 | 0.0632 |
| 951 | CD37 | L1 | Human | Cervix | CC | 2.03e-09 | -5.37e-01 | 0.0802 |
| 951 | CD37 | T1 | Human | Cervix | CC | 1.27e-20 | -6.18e-01 | 0.0918 |
| 951 | CD37 | T2 | Human | Cervix | CC | 3.96e-06 | -6.55e-01 | 0.0709 |
| 951 | CD37 | T3 | Human | Cervix | CC | 2.69e-33 | -6.53e-01 | 0.1389 |
| 951 | CD37 | LZE4T | Human | Esophagus | ESCC | 5.35e-08 | 3.32e-01 | 0.0811 |
| 951 | CD37 | LZE7T | Human | Esophagus | ESCC | 6.44e-07 | 6.67e-01 | 0.0667 |
| 951 | CD37 | LZE8T | Human | Esophagus | ESCC | 1.66e-02 | 3.09e-01 | 0.067 |
| 951 | CD37 | LZE22D1 | Human | Esophagus | HGIN | 1.13e-02 | 5.49e-01 | 0.0595 |
| 951 | CD37 | LZE24T | Human | Esophagus | ESCC | 4.34e-05 | 3.63e-01 | 0.0596 |
| 951 | CD37 | LZE6T | Human | Esophagus | ESCC | 3.54e-14 | 7.58e-01 | 0.0845 |
| 951 | CD37 | C21 | Human | Oral cavity | OSCC | 1.07e-08 | 4.26e-01 | 0.2678 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04640 | Cervix | HSIL_HPV | Hematopoietic cell lineage | 18/459 | 99/8465 | 4.97e-06 | 8.10e-05 | 6.54e-05 | 18 |
| hsa046401 | Cervix | HSIL_HPV | Hematopoietic cell lineage | 18/459 | 99/8465 | 4.97e-06 | 8.10e-05 | 6.54e-05 | 18 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CD37 | SNV | Missense_Mutation | c.90N>A | p.Phe30Leu | p.F30L | P11049 | protein_coding | tolerated(0.52) | benign(0.306) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD | |
| CD37 | insertion | Nonsense_Mutation | novel | c.765_766insTGTGATGAAAGATCTGATGAGAGTTCATTATACCACAGCTGACAA | p.Leu255_Glu256insCysAspGluArgSerAspGluSerSerLeuTyrHisSerTerGln | p.L255_E256insCDERSDESSLYHS*Q | P11049 | protein_coding | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| CD37 | SNV | Missense_Mutation | c.527N>A | p.Arg176His | p.R176H | P11049 | protein_coding | tolerated(0.48) | benign(0.003) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| CD37 | SNV | Missense_Mutation | novel | c.479N>G | p.Asp160Gly | p.D160G | P11049 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| CD37 | SNV | Missense_Mutation | c.709N>A | p.Trp237Arg | p.W237R | P11049 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
| CD37 | SNV | Missense_Mutation | c.458N>T | p.Cys153Phe | p.C153F | P11049 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-AM-5821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CD37 | SNV | Missense_Mutation | novel | c.68N>C | p.Phe23Ser | p.F23S | P11049 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CD37 | SNV | Missense_Mutation | c.214G>A | p.Ala72Thr | p.A72T | P11049 | protein_coding | tolerated(0.06) | benign(0.02) | TCGA-AJ-A3BH-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD | |
| CD37 | SNV | Missense_Mutation | novel | c.461G>A | p.Gly154Asp | p.G154D | P11049 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CD37 | SNV | Missense_Mutation | novel | c.73C>A | p.Leu25Ile | p.L25I | P11049 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 951 | CD37 | DRUGGABLE GENOME | IMGN529 | NARATUXIMAB EMTANSINE | ||
| 951 | CD37 | DRUGGABLE GENOME | antibody | 374883837 | ||
| 951 | CD37 | DRUGGABLE GENOME | TRU-016 | OTLERTUZUMAB | ||
| 951 | CD37 | DRUGGABLE GENOME | Otlertuzumab | OTLERTUZUMAB | ||
| 951 | CD37 | DRUGGABLE GENOME | BI-836826 | |||
| 951 | CD37 | DRUGGABLE GENOME | antibody | 374883838 | OTLERTUZUMAB | |
| 951 | CD37 | DRUGGABLE GENOME | antibody | 374883836 | ||
| 951 | CD37 | DRUGGABLE GENOME | TRU-016 | OTLERTUZUMAB |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |